José Baselga, who has resigned from his positions as physician-in-chief and chief medical officer at Memorial Sloan Kettering Cancer Center, is winding down his research and clinical activities at that institution, officials said.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
